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ABSTRACT: Introduction: Charcot–Marie–Tooth (CMT) disease
is a group of peripheral neuropathies affecting both motor and
sensory nerves. CMTX3 is an X-linked CMT locus, which maps
to chromosome Xq26.3–q27.3. Initially, CMTX3 was mapped to
a 31.2-Mb region in 2 American families. We have reexamined
1 of the original families (US-PED2) by next generation
sequencing. Methods: Three members of the family underwent
exome sequencing. Candidate variants were validated by PCR
and Sanger sequencing analysis. Conclusion: No pathogenic
coding variants localizing to the CMTX3 region were identified.
However, exome sequencing identified a known BSCL2
mutation (N88S). This study demonstrates the power of exome
sequencing as a tool to identify gene mutations for a small fam-
ily in the absence of statistically significant linkage data.
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Charcot–Marie–Tooth (CMT) disease is a genetically
and clinically heterogeneous group of inherited pe-
ripheral neuropathies, which affect both motor and
sensory nerves. CMT affects 1 in 2500 individuals, mak-
ing it the most commonly inherited neuromuscular dis-
order.1 X-linked CMT (CMTX) accounts for 15–20%
of cases.2–4 At present, 5 loci have been mapped
[CMTX1 (OMIM #302800), CMTX2 (OMIM
#302801), CMTX3 (OMIM #302802), CMTX4 (Cow-
chock, OMIM #310490), and CMTX5 (OMIM
#311070)].2,5–10 Two genes, gap junction beta 1 (GJB1)
and phosphoribosyl pyrophosphate synthetase 1
(PRPS1), have been identified for CMTX1 and
CMTX5, respectively.7,11
The CMTX3 locus was first described in 1991 in 2
American families. Combined LOD scores of 2.29
(DXS86; h 5 0.0) and 2.32 (DXS105; h 5 0.0) estab-
lished linkage to a 31.2-Mb region on Xq26–28.6 Over a
decade later, significant linkage in a large, multigenera-
tional UK and New Zealand family (CMT623) con-
firmed and refined the CMTX3 locus to a 5.7-Mb inter-
val (Xq26.3–27.1).12 Re-analysis of 1 of the original
American CMTX3 families (US-PED2) and a second
large Australian family (CMT193-ext) confirmed segre-
gation of a CMTX3 haplotype and prioritized the gene
search to the distal region of the 5.7-Mb interval based
on a founder haplotype in US-PED2.13
Initial reporting of the CMTX3 locus described US-
PED2 as an X-linked family, with no male-to-male trans-
mission and asymptomatic carrier females. Both US-
PED2 and CMT623 show axonal involvement with typi-
cal signs of CMT, including distal atrophy, high-arched
feet (pes cavus), and loss of deep tendon reflexes. Both
families show late onset of the disease, and US-PED2
displayed additional signs of spasticity.6,12
In this study we performed exome sequencing analy-
sis on family members from US-PED2. Several candidate
variants were identified; however, a previously reported
autosomal mutation for distal hereditary motor neu-
ropathy (dHMN) was discovered in this family.
METHODS
Exome sequencing and variant calling was performed
by Axeq Technologies (South Korea). DNA (5 lg)
from an affected man, an obligate carrier woman, and
an unaffected man. They underwent exon enrichment
using the illumina TrueSeq technology, followed by
100-bp paired-end sequencing on HiSeq 2000.
Sequence alignment and variant calling was performed
against the reference human genome (hg19) using
company customized analysis pipelines. Informed con-
sent from family members was obtained according to
protocols approved by the Sydney Local Health District
Ethics Committee, Concord Hospital (Sydney,
Australia).
The variant reports were filtered for known single-
nucleotide variations, insertions, and deletions using
the dbSNP 136 and 1000 genome databases. Tools pro-
vided by the Galaxy browser (http://main.-
g2.bx.psu.edu/) were used to identify shared variants
in the affected man and carrier mother. Further filter-
ing was achieved by eliminating variants present in the
unaffected brother and 20 in-house normal exomes
when compared with the affected man and obligate
carrier mother. Candidate variants were confirmed by
Sanger sequencing analysis. All experimentation was in
compliance with Australian laws.
RESULTS
Clinical examination of the proband (III-6)6 indicated
onset of weakness of the hands and feet at around 12
years of age. Initial examination at age 14 showed distal
weakness and wasting with clawed hands and flat feet.
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There was a stocking-glove sensory loss to touch and pro-
prioception. Deep tendon reflexes (DTRs) were 21 in
arms and 31 in legs with upgoing toes. There was a mild
postural tremor. Nerve conduction velocities were nor-
mal in sensory nerves but slowed in median and fibular
motor nerves (12 and 31 m/s). His course is one of
slowly progressive distal weakness and sensory loss. At 36
years of age, he remains ambulatory with the assistance
of ankle–foot orthotics (AFO). The carrier mother (II-
4)6 denies weakness at age 71 years and is ambulatory
without bracing. Osteoarthritic pain in hips and knees
limits her activity. A maternal uncle (II-2)6 had onset of
weakness around age 20 years. He has not been exam-
ined but is reported to have weakness of hands and
ankles.
Exome sequencing identified a total of 78,536
variants in the affected man. The filtering process
used to identify candidate novel variants shared in
the affected man and the obligate carrier mother is
shown in Figure 1a. A total of 393 shared novel var-
iants were identified.
Initially, the CMTX3 region (Xq26.3–27.1) was ana-
lyzed for the presence of candidate variants, but none
were identified. Having eliminated the CMTX3 locus, a
total of 393 novel variants still required validation. To
further filter the variants, we analyzed the patient’s
exome data for variants in known peripheral neuropa-
thy genes. This filtering strategy identified 1 reported
variant on chromosome 11 in the gene Berardinelli–
Seip congenital lipodystrophy 2 (BSCL2/seipin). The
base change corresponded to a previously identified
disease-associated missense mutation, c.263A>G
(N88S).14 Coverage analysis of this variant in the BSCL2
gene showed a total of 78 reads, with 48 reads, being
the alternate base. Sanger sequencing confirmed the
base change, and the variant segregated with the
affected man/carrier woman and was absent in the
unaffected sibling (Fig. 1b and c).
DISCUSSION
In this study we performed exome analysis on 1 of the
original American families (US-PED2) that contributed
to establishing linkage to the CMTX3 locus. In the
FIGURE 1. Identification and validation of a known BSCL2 gene mutation in US-PED2. (a) Filtering strategy to identify shared variants in the
affected man and obligate carrier woman. This method enabled the identification of potential pathogenic mutations in the CMTX3 region as well
as in known peripheral neuropathy genes. (b)Mapped exome sequence reads in the Integrative Genomics Viewer (IGV)23 for the affected man
from US-PED2. The gray bar represents the reference allele (T), and the colored base indicates the alternative allele (C). (c) Sequence traces
showing the validation of the change identified by Sanger sequencing. Both the affected and obligate carrier individuals were heterozygous for
the change c.263A>G (NM_032667). *Other regions represent the X chromosome, apart from the CMTX3 region, and the autosomes. [Color
figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
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original study this family was not large enough to dem-
onstrate significant linkage independently.6 We there-
fore undertook exome analysis for US-PED2 to screen
for variants in genes located on both the autosomes
and sex chromosomes.
We obtained DNA samples from 3 of the 12 family
members of the original pedigree,6 and confirmed that
coding variants were not present in the CMTX3 region.
The family was subsequently assessed for variants in
known peripheral neuropathy genes located on the
autosomes, and 1 known pathogenic mutation, N88S,
in the BSCL2 gene, was identified. This mutation has
been reported previously for phenotypes associated
with Silver syndrome, dHMN type 5, CMT type 2, and
hereditary spastic paraplegia.15 Studies of the N88S
mutation suggest a toxic gain of function that causes
improper folding of the BSCL2 protein. The incor-
rectly folded protein accumulates in the endoplasmic
reticulum (ER), which leads to ER stress and eventually
cellular dysfunction.16–19
Mutations in BSCL2 show a wide spectrum of clini-
cal features, which can affect both motor and sensory
neurons.15 One of the more unique clinical symptoms
reported in US-PED2 was spastic paraplegia.6 This clini-
cal feature has been reported in families with BSCL2
mutations.15 Interestingly, recent examination of US-
PED2 (K.M.) revealed that the carrier woman with the
BSCL2 mutation was clinically normal, thus reflecting
the phenotype for the obligate carriers of an X-linked
CMT disease.20 However, variability in penetrance of
the phenotype has been reported previously in families
with BSCL2 mutations in which individuals carrying the
disease mutation appear to be clinically normal.15,21,22
Incomplete penetrance of the N88S mutation is clearly
demonstrated in US-PED2.
For over a decade, US-PED2 had been classified as
X-linked CMT with evidence indicating linkage to the
CMTX3 locus.6 We therefore assumed a novel gene in
the CMTX3 locus may lead to the phenotype observed
in this family. The reported X-linked inheritance for
this family did not make screening genes associated
with spasticity a priority. Given the outcome of this
study, however, families with signs of spasticity, but that
are too small to show significant linkage, may benefit
from this approach. In this study, exome sequencing
proved to be a fast and cost-efficient method, as it gave
us the opportunity to examine both the region of inter-
est and the entire coding exome.
In conclusion, we have identified a known BSCL2
mutation in an original CMTX3 family (US-PED2) with
the aid of exome sequencing. Despite not finding a path-
ogenic variant in the CMTX3 region, this family can be
revisited once the gene mutation is identified in larger
families showing significant linkage to the CMTX3
locus.12,13 This study demonstrates the power of exome
analysis to identify gene mutations in the absence of stat-
istically significant linkage in small nuclear families.
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